ProCE Banner Activity

ACE-CL-001 Updated Analysis: Phase I/II Study of Frontline Acalabrutinib in Chronic Lymphocytic Leukemia

Slideset Download
Conference Coverage
BTK inhibitor demonstrates durable efficacy and tolerability in patients with previously untreated CLL in this early-phase study.

Released: December 18, 2018

Expiration: December 17, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology